# A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma

> **NCT07688187** · PHASE1 · RECRUITING · sponsor: **PeptiDream Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** PD-32766D (a Copper-64 [64Cu] labeled peptide)
- **DRUG:** PD-32766T (an Actinium-225 [225Ac] labeled peptide)

## Key facts

- **NCT ID:** NCT07688187
- **Lead sponsor:** PeptiDream Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-07
- **Primary completion:** 2029-05
- **Final completion:** 2029-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07688187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07688187, "A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07688187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*